Meriofert

Follicle‑stimulating hormone; Luteinising hormone, the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is used to stimulate follicular development and ovulation in women with anovulatory infertility and to support controlled ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and reproductive health centres worldwide.

Meriofert is a gonadotropin used in reproductive medicine to promote follicular growth and ovulation.

Infertility due to anovulation: supports follicular development and ovulation to improve chances of conception. Controlled ovarian stimulation for assisted reproductive technology: enhances multiple follicle development for IVF or ICSI cycles. Induction of ovulation in women undergoing intrauterine insemination: facilitates timed ovulation to increase success of IUI procedures.

Common Side Effects: - Injection site pain or bruising. - Mild abdominal discomfort or bloating. - Nausea or mild headache. - Transient hot flashes. - Mild ovarian hyperstimulation (elevated estradiol without severe symptoms). - Mild fatigue.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe) with rapid weight gain, ascites, or respiratory distress. - Multiple pregnancy (twins or higher order). - Allergic reactions including rash, urticaria, or anaphylaxis. - Thromboembolic events. - Ectopic pregnancy. - Severe abdominal pain indicating ovarian torsion.

Precautions should be observed when prescribing Meriofert to ensure patient safety and optimal outcomes.

Pregnancy: avoid use during established pregnancy unless specifically indicated. Breastfeeding: limited data; assess risk‑benefit before administration. Ovarian monitoring: perform ultrasound to detect excessive response. Allergy: confirm no hypersensitivity to any excipients. Concomitant estrogen therapy: may mask response; evaluate necessity. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert may interact with other hormonal agents and medications affecting coagulation.

Major Interactions (Avoid): - GnRH agonists: increase risk of severe ovarian hyperstimulation. - Clomiphene citrate: additive ovulation stimulation may lead to multiple follicles. - High‑dose estrogen therapy: can reduce efficacy of gonadotropin action.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding if injection site bruising occurs. - Thyroid hormones: adjust dosing if thyroid status changes. - Corticosteroids: may alter hormone metabolism; observe clinical response.